CELU Stock Overview
A clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Celularity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.94 |
| 52 Week High | US$7.97 |
| 52 Week Low | US$1.30 |
| Beta | 0.51 |
| 11 Month Change | 39.67% |
| 3 Month Change | -5.58% |
| 1 Year Change | 42.72% |
| 33 Year Change | -95.50% |
| 5 Year Change | -97.04% |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14
Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27Shareholder Returns
| CELU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.2% | -6.5% | -1.0% |
| 1Y | 42.7% | 14.6% | 30.3% |
Return vs Industry: CELU exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CELU exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CELU volatility | |
|---|---|
| CELU Average Weekly Movement | 36.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CELU's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CELU's weekly volatility has increased from 24% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 120 | Bob Hariri | www.celularity.com |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
Celularity Inc. Fundamentals Summary
| CELU fundamental statistics | |
|---|---|
| Market cap | US$64.26m |
| Earnings (TTM) | -US$112.83m |
| Revenue (TTM) | US$42.69m |
1.5x
P/S Ratio-0.6x
P/E RatioIs CELU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELU income statement (TTM) | |
|---|---|
| Revenue | US$42.69m |
| Cost of Revenue | US$16.97m |
| Gross Profit | US$25.72m |
| Other Expenses | US$138.55m |
| Earnings | -US$112.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.13 |
| Gross Margin | 60.24% |
| Net Profit Margin | -264.30% |
| Debt/Equity Ratio | 147.4% |
How did CELU perform over the long term?
See historical performance and comparison